Amneal’s Bevacizumab Biosimilar Brochure Rebuked By FDA’s OPDP

Alymsys Brochure Suggests Superiority To Avastin

 
• By Sue Sutter
  
The FDA said Amneal's brochure was misleading (Shutterstock)

More from Biosimilars

More from Products